

**Board of the meeting**

***Mahmoud Hassanein***

Chairman of physician Education Committee

***Mohamed Sobhy***

Chairman of Egyptian Working Group of Drug Therapy

***Aly Ramzy***

President of Egyptian Society of Cardiology

***Board and members of the  
Egyptian Working group of  
Cardiovascular Drug Therapy***

***are appreciating the participation of the  
Chairman and members from the  
European Working group of Cardiovascular  
pharmacology and Drug Therapy***

### **Sharm El Sheikh, the meeting hosting city**

*Located in the Sinai Peninsula of Egypt is considered the strategic passageway, the meeting point between Asia and Africa, and the cradle of great civilizations.*

*It is no wonder that the stories of heavenly religions that dawned on humanity can be eloquently narrated by the soil of Sinai.*

*With its diverse features of environment that combine together history, tourism, industry and agriculture, it has become a main attraction for tourists, travelers and businessmen. Sharm El-Sheikh, the biggest and most important city of Sinai, lies at the southern flank of the Peninsula where the two gulfs of Aqaba and Suez meet with the Red Sea.*

*Sharm El-Sheikh, apart from its military strategic position, was considered for more than 25 years an isolated part of Egypt. Only after the liberation war and Egypt's victory in 1973, and the ensuing peace agreement, the wonderful city of Sharm El-Sheikh emerged as a promising resort laden with many prospective potentials of prosperity. Since then a new era emerged in the history of Sinai and its largest city.*

*A place that witnessed some of the greatest stories in the history of Jewish, Christian, and Muslim nations, and played a major part in twentieth century world politics, is now one of Egypt's chief tourist attractions. Located on the eastern shore at the southern tip of the Sinai Peninsula, and consisting of a series of bays, Sharm El Sheikh has turned out to be one of the finest places for people to enjoy the best sun, sea, sand, and hospitality of its residents. A decade ago the city was mainly known as "a fishing and diving zone" thanks to its numerous bays that incubate the endless kinds of fish and coral reefs.*

*Sharm El Sheikh is basically divided into three main regions: Sharm el Maya, where the airport is based as well as many private yachts and pleasure boats that take divers to the best diving spots in the area like Ras Mohammed. Ras Om El Seed, famous for its coral reefs, has a very high cliff where many hotels are situated. However, the biggest tourist attraction in the city is Naama Bay. This long bay is where most of the hotels, shopping malls, and nightlife can be found.*

## **Tourist attractions**

*Sharm El-Sheikh city offers a variety of tourist attractions ranging from a dramatic mountain backdrop to stretches of golden beaches on matchless waters.*

*Coral reefs, under water and marine life, unmatched anywhere in the world, offer a spectacular and dazzling time for divers. There is wide room for scientific tourism with diversity in marine life species; 250 different coral reefs and 1000 species of fish.*

*These natural resources together with its proximity to European tourism markets have stimulated the rapid growth of tourism boom that the region is currently experiencing. The Bedouin culture with the colorful handicraft stands alone as a scene worth visiting. At the south borderline of the city lies Ras Mohammed, this has been declared as a National Park in 1983. The park contains a variety of stunning geological features, including uplifted coral reefs, alluvial plains, Wadis (valleys), granite and Sandstone Mountains and soft dunes.*

*Ras Mohamed is also home to many terrestrial species including foxes, gazelles, reptiles, ibexes and migratory birds such as White Storks and Raptors.*

*There is also a forest of Mangroves trees, which provide valuable breeding areas with habitat for both birds and fish.*

*This marine national park is considered to be one of the most interesting diving sites in the world, with much diversity and rich coral life, some thousand different fish species and 150 coral types.*

*Nabq Park borders the city from the north. It is an outstanding natural area containing varied ecosystems and habitat types. Between which is the Mangroves (*Avicennia marina*) -one of the most important species combined with 134 plant species spread across the park.*

*Visitor of Sharm El-Sheikh city will get a glimpse of cultural and religious tourism by visiting historical sites available at an arm's stretch.*

*At the East of the city lies The Monastery of St. Catherine. It is one of the very few early Christian building complexes that have not been destroyed or reconstructed several times over the centuries. The monastery spiritual heritage is beyond estimation.*

*Its architecture wall, paintings, codices, icons, historical documents, and illuminated manuscripts represent great treasures of the world's Legacy. The monastery is still functioning and hosting around 22 Greek Orthodox monks.*

*Mount St. Catherine is the highest peak in Egypt, towering up to 2,641 meters above sea level. There, stands at 2,285-meter high mount Moses, which is renowned as the place where Prophet Moses received the Ten Commandments.*

*Muslim, Christian and Jewish pilgrims come from all over the world to watch the moments of sunrise from the peak. On a clear day eyesight can cover over all Sinai and even reach the sea.*

## **Address during the meeting**

*From January 21<sup>th</sup> till January 23<sup>th</sup>, 2010*

*Grand Rotana Hotel*

*Sharm El Sheikh, Egypt*

## **Language**

*The official language is English.*

*All lectures and presentations will be held in the English language only .*

*There will be no translation available*

## **Conference website**

*[www.cdt-egypt.com](http://www.cdt-egypt.com)*

## **Electricity**

*The electricity supply in Egypt is 220 Volts, 50 Hz.*

*Most hotels also provide 110 Volts outlets for shavers*

## **Currency banking** (rates are subjects to market fluctuations)

*Egyptian Pound is the official currency in Egypt. Foreign currency exchange is available in most of the hotels, banks and currency exchange offices.*

**Exchange rate of 1 US\$ = 5.43 EGP**

**Exchange rate of 1 € = 7.6 EGP**

*ATM machines are available all through the city and at the vicinity of all conference hotels*

## Organizational Notes

**\*\*Phones should be turned off during the sessions\*\***

### **Registration Hours**

Registration desk will be ready on Thursday, January 21<sup>st</sup> at 02:00 pm

Registration desk will be ready on Friday, January 22<sup>nd</sup> at 04:00 pm

**NO EXTRA COUPONS FOR LUNCH OR COFFEE BREAK  
WILL BE AVAILABLE (NO SALE)**

### **Scientific rooms Hours**

Scientific activities will start on Thursday, January 21<sup>st</sup> at 06:00 pm

Scientific activities will start on Friday, January 23<sup>th</sup> at 05:30 pm

### **Lunch hours:**

Lunch will be served

Thursday at main restaurant

from 13:00 to 15:30

Friday at main restaurant

from 13:00 to 15:30

### **Dinner Hours:**

Dinner will be served

Thursday at main restaurant

from 22:30- 23:30

Friday at main restaurant

from 22:30- 23:30

## Audiovisual Guidelines

- Please use a PC (IBM Compatible) not Apple Macintosh formats.
- Computers used in the conference are PCs loaded with
- Microsoft Office 2007.
- Please use Microsoft PowerPoint XP or later version to prepare your presentation.
- If your presentation includes embedded movies and/or sound, use the "Pack and Go / Package for CD" feature. This is found under the file menu. Pack and Go makes sure that all elements of your presentation are compiled together. This is especially important if you are saving to a CD. You risk not having all of your movie clips, graphics and sound clips if you use a standard "Save" or "Save as."
- If your presentation includes movies or embedded fonts, be sure, when creating a backup disk, to create a folder that includes your presentation and movie files or sound clips. This will insure that all the tools used to create the presentation are readily accessible on the show site, should the need arise to modify the presentation.
- Please remember that your movies should be in MPEG1 format. AVI files might not work properly on all computers unless special codec is used. MOV is not a compatible format to be run inside PowerPoint.
- DICOM players will not be available in all computers serving the conference.
- Speakers are not allowed to use their personal laptops whatever the reason is. Strict rules are applied in this matter. Apple users must prepare a PC compatible CD or DVD loaded with their presentation(s).
- Only digital media is allowed as a tool to present data, namely CDs, DVDs, Flash memory &/or external hard drive. No 35mm physical slides are allowed. No video tapes. No Transparencies. No Whiteboard. No Bluetooth mobile phones.
- Computers inside halls are not connected to the internet.
- Speakers MUST handle their PRESENTATION CDs one hour AT LEAST before the beginning of the session.
- The duration of the presentation is controlled digitally through computer software that will give a warning 3 and 1 minute(s) before the end of time end the view when time is up, thus we value your understanding to stick to the dedicated time.  
We are glad to help any speaker in case there is a need of any assistance.

## Audiovisual & Information Technology Support

### R M Solutions

Dr. Maged Kassem

Cellular: +20 12 3925628

E-mail: [drmagedkassem@gmail.com](mailto:drmagedkassem@gmail.com)

## **Acknowledgment**

*Special thanks and Appreciation to our major contributors*

***Sanofi Aventis***

***Novartis***

***Merck Sharp and Dohme***

***Pfizer***

***Multipharma***

***Boehringer Ingellhim***

**Organizing Office in Charge**

**ICOM**



**International Center for Organization & Marketing**

**Authorized Accreditation Provider  
American Academy of Continuous Medical Education-AACME**

**Address:** El Asdekaa building (2) – Masged El Asdekaa st. Garden city  
Smouha - Alexandria – Egypt.

**Tel:** + 203- 420 4849 + 203- 4249072

**Fax. :** + 203- 420 4849

**Cellular** + 2010 122 4849 +2012 2480206

**E- mail:** icom@dataxprs.com.eg

info@icomgroup.org

**Website: [www.icomgroup.org](http://www.icomgroup.org)**

## Zannad, Faiez

BORN July 23<sup>rd</sup> 1951, Monastir, TUNISIA,  
NATIONALITY France



### **Positions and Employment**

- Professor, Medical Faculty of the Henri Poincaré University of Nancy, France
- Head, Division of Heart Failure, Hypertension and Preventive Cardiology/ department of Cardiovascular Disease of the Academic Hospital (CHU) of Nancy, France
- Chairman, ICALOR, Lorraine Region Heart Failure disease management program. (<http://www.icalor.fr>)
- Director, Clinical Investigation Center, Inserm-CHU of Nancy, France, since 1995 (<http://www.cic-nancy.fr/cic/>)
- Coordinator, French Cardiovascular Clinical Investigation Centers
- Co-chairman, European Drug Development Hub (EDDH), Nancy, France.

### **Other Experience and Professional Memberships**

**Steering Committee Membership:** APSI, FIRST, CIBIS I and II (Executive committee), RALES (Executive committee), CAPRICORN, FOSIDIAL (Chairman), VALIANT, RECOVER, MOXCON, EPHEBUS (Executive committee), AURORA (Executive committee), EVEREST (Executive committee), HF-ACTION, EMPHASIS-HF (Chairman), SERVE-HF, RELAX-HF, ASTRONAUT, RIGHT-1, AXIOM-ACS (Executive committee), EXAMINE (Executive committee), NECTAR-HF (Executive committee), ALBATROSS

**Critical Event Committee:** CAPRICORN, RESPECT, SCOUT

**Data and Safety Monitoring Board:** HEAAL, ASPIRE

**Protocol Writing Groups:** RALES, CAPRICORN, CIBIS II, EPHEBUS, EVEREST

**Editorial Board Member:** *Journal of Hypertension* (1999– 2003), *Journal of Cardiovascular Pharmacology*, (1998 – 2002), *Cardiology* (2005-ongoing)

**Co-Editor-in-Chief:** *Fundamental and Clinical Pharmacology*, the official journal of the European Pharmacology Societies Federation (EUPHAR)

**Co-Chair:** Annual international meetings on Acute Heart Failure Syndromes

**Co-Chair:** Annual international meetings on Biomarkers in Heart Failure

**Co-Chair:** Annual international meetings on Cardiovascular clinical trials (CVCT Forum and CVCT Workshop) (<http://www.globalcvctforum.com>)

Board member: European Society of Cardiology Heart Failure Association – year 2008-2011

**Chairman:** Board of the French Society of Hypertension – year 2007-2008

**Chairman** European Society of Cardiology pharmacology and drug Therapy Working Group – year 2008-2010

### **Honors**

**Fellow,** European Society of Cardiology (FESC) – 1996



## B. Research Support

**European Union:** Network of excellence InGenious HyperCare. Transition from hypertension to heart failure 2006-2010 (<http://www.hypercare.eu/>)

**Inserm:** Clinical Research Network 2002, ongoing..: Transition mechanisms from Metabolic syndrome to heart failure

**Inserm:** CIC translational research grant 2007-2010: Biomarkers of Mineralocorticoid receptor activation.

**French Government and Lorraine region:** « Contrat de Plan Etat Région” Therapeutic Innovation and Health Technology. 2007-2013. Biomarkers of Cardiovascular ageing and disease.

## C. Publications

Total number of peer reviewed publications in Pub Med:

275

<http://www.gopubmed.org/web/gopubmed/search?q=%22Zannad+F%2F15022296%22%5Bauthor%5D>

## D. Major field of interest:

Hypertension, heart failure, clinical trials

## E. Summary of the main outcomes of research

Significant contribution in advances in heart failure treatment, through major clinical trials, mainly with aldosterone antagonists (RALES, EPHESUS), but also with beta-blockers (CIBIS, CAPRICORN) and vasopressin antagonists (EVEREST), which has led to the approval of new drugs in this area and change in international guidelines.

- Specific interest in biomarkers in CV disease. Emphasis on clinical research on the value of markers of extracellular matrix biomarkers in heart failure and ischemic heart disease as well as Biomarkers of Mineralocorticoid receptor activation. Results show that fibrosis biomarkers may predict outcome and describe one mechanism of action of aldosterone antagonists in heart failure.
- Recent interest into mechanisms of Transition from hypertension to heart failure. European Union: Network of excellence InGenious HyperCare. 2006-2010. Work in progress.
- First author of the first randomized controlled trial of CV prevention in hemodialysis patients (FOSIDIAL). Results show a potential benefit of ACE inhibitor therapy to decrease CV morbidity and mortality in patients with ESRD and left ventricular hypertrophy. The trial data also described eh size of CV outcomes in this very high risk population.
- Contribution to clinical trial science an methodology in CV disease, through various publications and organisation of CardioVascular Clinical Trialists meetings ([www.globalcvctforum.com](http://www.globalcvctforum.com))

## ANGELES ALONSO GARCIA

I was born and raised in Madrid, Spain.

In 1979 I graduated from the School of Medicine at the Universidad Autónoma de Madrid and

later in 1991 I successfully completed my Ph.D

at the Faculty of Medicine. I began my clinical experience with as a resident doctor in the Intensive Care Unit at the Hospital La Paz (Madrid) and then in the Department of Cardiology at the Academic Hospital Puerta de Hierro (Madrid) where I went on to become a member of staff of the Department of Cardiology Service in 1987 to the present date (Coronary Care Unit, Hospitalisation Unit). In 2000 I became a member of the Committee for Ethics and Clinical Investigation and a Member of the Committee for Mortality. Two years later I was promoted to Senior Consultant of the Cardiology Department at the Hospital Universitario Puerta de Hierro (Majadahonda). I am an Honorary Professor at the Department of Medicine in Cardiology at the Faculty of Medicine, Universidad Autónoma de Madrid and have also been Coordinator, Chairman and speaker of several post-degree Ph D Courses at the Academic Hospital Puerta de Hierro de Madrid on Cardiovascular Topics: Hipertensión, Cardiac Emergencies, Heart Failure and Cardiac pacing. I have been a member of the Spanish Society on Cardiology (SEC) since 1986, a member of the Heart Failure, Ischemic Diseases, Women and CV Disease, Pharmacology Working Groups of the Spanish Society of Cardiology, General Vice-Secretary elect of the Spanish Society of Cardiology: 1999-2001, General Secretary of the Spanish Society of Cardiology: 2001-2003 and President of the International Relations Department of the Spanish Society of Cardiology and Member of the Editorial Committee of the Spanish Heart Journal.



I have also been a Fellow of the European Society of Cardiology since 2001, a member of the WG of Heart Failure and Acute Heart Diseases of the European Society of Cardiology ESC, a member of The Euro Heart Survey Committee of the European Society of Cardiology ESC from 2002-2004, National Coordinator of the Euro Heart Survey Program of the European Society on Cardiology 2000-2004, a member of the Clinical Practice Guidelines Committee of the European Society of Cardiology ESC 2000-2004, a member of the Task Force of Stable Angina Guideline of the ESC 2006, a member of the Regulatory Committee of the ESC until the present date and a member of the General Coordinating Committee of The Euro Heart Survey Programm until the present date.

## Finn Gustafsson

Finn Gustafsson, MD, PhD (born 1968) is a consultant cardiologist at Rigshospitalet in Copenhagen, Denmark. After graduation from Faculty of Medicine, University of Copenhagen in 1994, he subsequently completed his training in cardiology and internal medicine in various hospitals in Copenhagen. In 2000 he defended a PhD thesis in microvascular physiology at University of Copenhagen. Following a clinical fellowship at Toronto General Hospital, Ontario, Canada, he now is a staff cardiologist in the heart failure and transplantation program at Rigshospitalet. Major scientific areas of interest include epidemiology and intervention in heart failure, as well as medical aspects of cardiac transplantation and left ventricular assist device therapy. He has served as an investigator and on steering committees of several clinical trials in the fields of heart failure and transplantation. He has authored or co-authored more than 90 papers in international, peer-reviewed medical journals as well as co-authored books and monographs on heart failure. He has been a member of the nucleus of the Working Group for Cardiovascular Drug Therapy of the European Society of Cardiology since 2006.

### **Selected recent publications:**

Rosenberg J, Schou M, Gustafsson, Badsckjær J, Hildebrandt P: Prognostic threshold of NT-proBNP in primary care. *Eur Heart J* 2009; 30: 66-73.

Gustafsson F, Schou M, Videbæk L, Dridi N, Ryde H, Handberg J, Hildebrandt P on behalf on the Danish Heart Failure Clinics Network: Incidence and predictors of hospitalization or death in patients managed in multidisciplinary heart failure clinics. *Eur J Heart Fail* 2009; 11:413-419.

Klovaite J, Gustafsson F, Sander K, Mortensen SA, Nielsen LB: Severely impaired von Willebrand factor-dependent platelet aggregation in patients with continuous-flow left ventricular assist device (HeartMate II). *J Am Coll Cardiol* 2009; 53:2162-2167.

Gustafsson F, Barth D, Delgado DH, Nsouli M, Sheedy J, Ross HJ: The impact of everolimus versus mycophenolate on blood- and lymphocyte cyclosporine exposure in heart transplant recipients. *Eur J Clin Pharmacol* 2009; 65:659-65

Andersen, M, Videbæk R, Boesgaard S, Sander K, Hansen PB, Gustafsson F: Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (Heartmate II). *J Heart Lung Transplant* 2009; 28: 733-735.

Møller DV, Pham TT, Gustafsson F, Hedley P, Ersbøll MK, Bundgaard H, Andersen CB, Torp-Pedersen C, Køber L, Christiansen M: The role of lamin A/C mutations in Danish patients with idiopathic dilated cardiomyopathy. *Eur J Heart Fail* 2009; 11:1031-1035.

Sheshgiri R, Gustafsson F, Sheedy J, Xiao R, Librach CL, Rao V, Ross HR , Delgado DH: Everolimus but not Mycophenolate Mofetil Therapy is Associated with Soluble HLA-G Expression in Heart Transplant Patients. *J Heart Lung Transplant* 2009; 28:1193-7

Gustafsson F, Ross HJ: Pathophysiology of exercise intolerance in heart failure. In Kirklin J, Branner N, and Jessup M (eds.) *Advanced Heart Failure*. ISHLT monograph, Vol. 3 (1), Elsevier 2009.

## F. Follath MD, FESC

Medical education: Medical School University of Basel, Switzerland.

Postgraduate specialisations: Internal medicine, cardiology and clinical pharmacology at the University Hospitals in Basel and Geneva, Switzerland and at the Royal Postgraduate Medical School, Hammersmith Hospital, London

Positions held: Professor of medicine, University of Zürich, Head of the Department of Medicine at the University Hospital, Zürich Switzerland (1990 – Aug. 31. 2005). Professor of Clinical Pharmacology, University Hospital, Basel (1981 -1990)

Present :

Emeritus professor of Medicine University of Zürich, Chairman of the Steering Group for Drug Therapy, University Hospital, Zürich

Cardiologist at the Center for Cardiovascular Diseases, Clinic im Park (Hirslanden Group), Zürich

Member of the Nucleus of the Working Group for Cardiovascular Pharmacology and Drug Therapy (Senior advisor)

Member of the Task Force for Acute Heart Failure of the ESC

Clinical and experimental research interests:

Epidemiology and drug therapy of acute and chronic heart failure.

Studies with inotropic agents.

Drug treatment of cardiac arrhythmias. Inflammatory heart diseases.

Basic research in drug metabolism and pharmacokinetics of antiarrhythmic agents.

Drug elimination and dosage in patients with renal dysfunction.

Member of Steering Groups in several international multicenter trials (PRIME II, CIBIS II and III, EURO-HF I and II, IMPROVEMENT, LIDO. ALARM-HF)

Publications and lectures:

More than 400 papers , editorials and reviews in international journals of cardiology and internal medicine. Numerous invited lectures at international congresses and symposia.

Honours: Honorary member of the Hungarian Society of Cardiology and of the Swis

Society of Internal Medicine, Honorary Fellow of the European Federation of Internal Medicine

## **JOSÉ ANTONIO GARCÍA-DONAIRE, M.D, Ph.D**

Data of Birth: 1974/08/22

City: MADRID

ID: 1927719-C

Office Number: +34-913908198

Cell Number: +34-626776191

e-mail: [docdonaire@terra.es](mailto:docdonaire@terra.es)



### **ACADEMIC INFO**

2009: Doctoral Thesis with “A” cum laude degree

2001-: Nephrologist at Hospital Universitario 12 de Octubre. Universidad Complutense. Madrid

2001-2002: Post-grade investigator with “A” degree .

1992-1998: Graduate in Medicine and Surgery. Universidad Complutense de Madrid

Member of several scientific societies:

- Spanish Society of Nephrology (SEN)
- Spanish Society of Hypertension (SEH-LELHA)
- Spanish Group for the study of arterial hypertension (GESTHA)
- Association for the prevention of cardiovascular risk (PRECAR)

### **TEACHING EXPERIENCE**

- Speaker at national and internacional Hypertension and Nephrology Congresses. Investigator and coordinator of hypertension and cardiovascular risk clinical trials.

- Coordinator of excellence courses in cardiovascular risk for general practitioners, specialists and pharmacists.

## **BOOKS: 12**

1. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure after single therapy (Ex-Fast) study. Journal Scan. Ed. SPA, SL, 2009
2. ESTHER. Estudio sobre hipertensión y riesgo cardiovascular. Documento de conclusiones. Ed. SPA, SL, 2009
3. Experiencias Clínicas en Nefrología. HTA, protección renal y riesgo vascular. Ed. ProDrug Multimedia, S.L., 2008
4. The Aging Kidney in Health and Disease. Capítulo: Hypertension. Ed. Springer, 2008
5. Optimización del tratamiento antihipertensivo adaptado al perfil del paciente. Capítulo: Paciente hipertenso con microalbuminuria. Ed. Euromedice, 2008
6. Casos clínicos de HTA en pacientes de riesgo. Ed. Euromedice, 2007
7. Manual de Diagnóstico y Terapéutica Médica Hospital 12 de Octubre. 6ª Ed. Capítulo "Hipertensión Arterial" e "Insuficiencia renal crónica". Ed. Egraf, 2007
8. Hipertensión Arterial. Preguntas Claves. Respuestas útiles. Ed. Drug Farma, 2007
9. Dilemas Clínicos en Hipertensión. Ed. SPA S. L, 2007
10. HTA y órganos diana. Imágenes clínicas y anatomo-patológicas. Ed. You & Us, S.A, 2006
11. Salud Laboral y riesgo cardiovascular. Capítulo: Daño orgánico renal. 2006
12. Avances en el manejo de la Hipertensión Arterial en el anciano. Capítulo Abordaje terapéutico (II). Los nuevos fármacos y las asociaciones. Ed. Glosa. 2005

## **INTERNATIONAL JOURNAL PUBLICATIONS: 36**

## **ABSTRACTS AND CONFERENCES AT NATIONAL AND INTERNATIONAL CONGRESSES: 50**

## **PETER JAN LANSBERG**

Name: Lansberg, Peter Jan  
Place of birth: Amsterdam, The Netherlands  
Date of birth: April 26, 1955  
Citizenship: Dutch



### **EDUCATION**

A. 1984 and 1986 Undergraduate: University of Amsterdam;  
Bachelor and Masters Degree of Medicine,  
Amsterdam, The Netherlands

1988 University of Amsterdam

Medical Doctor's degree

B. 1989 Resident in Internal Medicine  
Slotervaart Medical Center, Amsterdam

Internal Medicine

Pulmonology

C. 1993 Doctorate Thesis in Medicine  
The Molecular Basis and Treatment of Familial

### **POSITIONS**

1996

Senior staff member and lecturer of the Department of Vascular Medicine,  
Academic Medical Center, University of Amsterdam, Amsterdam.

1993

Founder and Coordinator of the Dutch Lipid Clinics Network, Academic Medical  
Center, University of Amsterdam, Amsterdam

2008

Coordinator of Durrer Cardiogenetic Research Center – Inter University Cardiology  
Research Institute/National Academy of Science of the Netherlands

2006 - 2007

Visiting Professor Department of Cardiology and Vascular Medicine, Dr. Kariadi  
Hospital, University of Diponegoro, Semarang, Indonesia

2000 - 2006

Director of the national foundation for tracing Familial Hypercholesterolemia (FH)  
patients (Stichting Opsporing Erfelijke Hypercholesterolemie - StOEh).

As of January 2006 StOEh Ambassador responsible for international relationships  
and international research projects

1993-2006

Head of the Amsterdam Lipid Clinic, Slotervaart Medical Center, Amsterdam.

1990-2006

Senior supervisor data management, Amsterdam Lipid Clinics, Slotervaart Medical Center and Academic Medical Center, University of Amsterdam, Amsterdam.

1999-2005

Member of the national task force for implementing electronic patients records in internal medicine.

2000-2006

Member of the National Forum for Biotechnology and Genetics

2004-2005

Member of the Amsterdam taskforce for implementing electronic prescriptions

### **PhD THESIS**

Co-promotor for thesis “ Diagnostic Criteria and Risk Factors of Cardiovascular Disease in Familial Hypercholesterolemia” ; E.S. van Aalst – Cohen

Promotor: prof. Dr. J.J.P. Kastelein

Co-promotors: Dr. M.D. Trip and dr. P.J. Lansberg

## Faculty of the meeting

- **Abdel Fatah Ferer** (Zagazig,Egypt)
- **Abdel Moniem Ibrahim** (Cairo,Egypt)
- **Abdel Rahman Sharaf** (Azhar,Egypt)
- **Adel El Etriby** (Ain Shams,Egypt)
- **Ahmed El Ghalid** (Suez Canal,Egypt)
- **Ahmed El Hawary** (Suez Canal,Egypt)
- **Ahmed Magdy** (NHI,Egypt)
- **Ahmed Nassar** (Ain Shams,Egypt)
- **Ahmed Rozza** (Azhar,Egypt)
- **Ahmed Shafie Ammar** (Zagazig,Egypt)
- **Aly El Abd** (Ain Shams,Egypt)
- **Aly Ramzy** (Ain Shams,Egypt)
- **Amin Omran** (Alexandria,Egypt)
- **Amr Hassan Moustafa** (Cairo,Egypt)
- **Amr Zaki** (Alexandria,Egypt)
- **Angeles Alonso** (Madrid,Spain)
- **Ashraf Reda** (Menoufiya,Egypt)
- **Atef El Bahary** (Port Said,Egypt)
- **Ayman Abou El Magd** (Azhar,Egypt)
- **Ayman Saleh** (Ain Shams,Egypt)
- **Ehab Attia** (Ain Shams,Egypt)
- **Ekram Sadek** (Tanta,Egypt)
- **Faiez Zannad** (Nancy, France)
- **Fatma Abou El Einein** (Alexandria,Egypt)
- **Ferenc Follath** (Zurich, Switzerland)
- **Finn Gustafsson** (Copenhagen , Denmark)
- **Galal El Saeid** (Cairo,Egypt)
- **Gamal Abou El Nasr** (NHI,Egypt)
- **Hamdy Soliman** (NHI,Egypt)
- **Hani Abdel Razek** (NHI,Egypt)
- **Hany Ragy** (NHI,Egypt)
- **Hazem Khamis** (6 october,Egypt)
- **Hesham Abo El Enin** (Banha,Egypt)

- **Hossam Kandeel** (Cairo,Egypt)
- **Jose Antonio Garcia Donaire** (Madrid,Spain)
- **Kamal Mahmoud** (Alexandria,Egypt)
- **Khairy Abdel Dayem** (Ain Shams,Egypt)
- **Magdy Rashwan** (Alexandria,Egypt)
- **Mahmoud Hassanein** (Alexandria,Egypt)
- **Medhat Asmawy** (Tanta,Egypt)
- **Mohamed ElSetteha** (Tanta,Egypt)
- **Mohamed Gamal** (Assiut,Egypt)
- **Mohamed Sobhy** (Alexandria,Egypt)
- **Mohamed Wafaei Abou El Enein** (Zagazig,Egypt)
- **Mohamed Zaki** (NHI,Egypt)
- **Mohsen Ibrahim** (Cairo,Egypt)
- **Mokhtar Gomaa** (Azhar,Egypt)
- **Moustafa Nawar** (Alexandria,Egypt)
- **Nabil Farag** (Ain Shams,Egypt)
- **Nasser Taha** (Minia,Egypt)
- **Omar Awwad** (Ain Shams,Egypt)
- **Ossama Sanad** (Banha,Egypt)
- **Peter Jan Lansberg** (Amsterdam, Netherlands)
- **Ramez Guindy** (Ain Shams,Egypt)
- **Ramzy El Mawardy** (Ain Shams,Egypt)
- **Roberto Ferrari** (Italy)
- **Sahar Azab** (Alexandria,Egypt)
- **Sameh Shahin** (Ain Shams,Egypt)
- **Samir Abdel Kader** (Assiut,Egypt)
- **Sherif El Tobgy** (Cairo,Egypt)
- **Tarek El Zawawy** (Alexandria,Egypt)
- **Wael El Naggar** (Cairo,Egypt)
- **Wagdy Ayad** (Alexandria,Egypt)
- **Wagdy Galal** (Ain Shams,Egypt)
- **Yehia Keshk** (Assiut,Egypt)

**Thursday, 21st of January 2010**

**05.30-6.00 pm**

**Welcome & opening Speeches**

***Mahmoud Hassanein***

Chairman of physician Education Committee

***Mohamed Sobhy***

Chairman of Egyptian Working Group of Drug Therapy

***Faeiz Zannad***

Chairman of European Working Group of Drug Therapy

***Roberto Ferrari***

President of European Society of Cardiology

***Aly Ramzy***

President of European Society of Cardiology

**6:00-7:00pm**

**State of the Art**

**(1)**

20 min each talk and 10 min discussion

**Moderators**

***Aly Ramzy***

***Mokhtar Gomaa***

**Commentators:**

***Abdel Moniem Ibrahim***

***Ahmed Nassar***

***Aly El Abd***

***Ramzy El Mawardy***

***Sherif El Tobgy***

***Ramez Guindy***

**New options for the therapeutical treatment of angina**

***Roberto Ferrari***

***(Italy)***

**Expanding the frontiers of Renin-Angiotensin and Aldosterone systems inhibition in cardiovascular disease.**

***Faiez Zannad***

***(Nancy, France)***

**Middle East and the Arab world, emerging to Cardiovascular trials. Cultural, organisational and regulatory aspects. (from CVCT 2009)**

***Mohamed Sobhy***

***(Alexandria, Egypt)***

**7:00-8:30pm**

**CDT European Session (1)**

20 min each talk and 10 min discussion

**Moderators**

***Mohsen Ibrahim***

***Moustafa Nawar***

**Commentators**

***Abdel Rahman Sharaf***

***Ahmed Rozza***

***Omar Awwad***

***Nabil Farag***

***Samir Abdel Kader***

***Tarek El Zawawy***

**The future of managing Chronic Heart Failure: Drugs on the horizon?**

***Angeles Alonso***

***(Madrid,Spain)***

**Acute Heart Failure: Clinical Guidelines**

***Ferenc Follath***

***(Zurich, Switzerland)***

**Statins in Heart Failure: Lessons learned**

***Angeles Alonso***

***(Madrid,Spain)***

**Drug therapy for cardiovascular prevention in high risk patients :  
Lessons from recent trials**

***Jose Antonio Garcia Donaire***

***(Madrid,Spain)***

**8:30-9:45pm**

**Chronic Stable Angina (Part 1)**

15 min each talk and 15 min discussion

**Egyptian Working group of Cardiovascular Drug Therapy  
Physician Education CME course  
3<sup>rd</sup> year Activity**

**Moderators**

***Amin Omran***

***Ekram Sadek***

***Yehia Keshk***

**Commentators**

***Amr Zaki***

***Fatma Abou El Einein***

***Hamdy Soliman***

***Hesham Abo El Enin***

***Kamal Mahmoud***

***Mohamed Gamal***

**Introduction**

***Mahmoud Hassanein***

***(Alexandria,Egypt)***

**Diagnosis & assessment of chronic stable angina**

***Magdy Rashwan***

***(Alexandria,Egypt)***

**Risk Stratification in chronic stable angina**

***Mohamed Wafaei Abu El Enein***

***(Zagazig,Egypt)***

**General messages and Cardiovascular risk reduction in patients with stable angina**

***Ashraf Reda***

***(Menoufiya,Egypt)***

**Friday , 22nd of January 2010**

**05.30-6.30 pm**

**State of the Art**

**(2)**

25 min each talk and 10 min discussion

**Moderators**

***Khairy Abdel Dayem***

***Galal El Saeid***

**Commentators**

***Ahmed Magdy***

***Ayman Abou El Magd***

***Amr Hassan Moustafa***

***Gamal Abou El Nasr***

***Medhat Asmawy***

***Sameh Shahin***

**Advances in anti-coagulant therapies – the impact of the RE-LY study**

***Roberto Ferrari***

***(Italy)***

**Evidence based medicine: From Clinical trials to daily practice**

***Faiez Zannad***

***(Nancy, France)***

**6:30-08:00pm**

**Chronic Stable Angina (Part2)**

15 min each talk and 15 min discussion

**Egyptian Working group of Cardiovascular Drug Therapy  
Physician Education CME course  
3<sup>rd</sup> year Activity**

**Moderators**

**Wagdy Galal**

**Hani Abdel Razek**

**Commentators**

**Ahmed Shafie Ammar**

**Atef El Bahary**

**Ayman Saleh**

**Mohamed ElSetteha**

**Ossama Sanad**

**Sahar Azab**

**Pharmacologic therapy of chronic stable angina (Part 1)**

**Adel El Etriby**

**(Ain Shams,Egypt)**

**Pharmacological therapy of chronic stable angina (Part 2)**

**Ehab Attia**

**(Ain Shams,Egypt)**

**Pharmacological therapy of chronic stable angina (Part 3)**

**Hossam Kandeel**

**(Cairo,Egypt)**

**Myocardial Revascularization for chronic stable angina**

**Hany Ragy**

**(NHI,Egypt)**

**Conclusions & Recommendations**

**Mohamed Sobhy**

**(Alexandria,Egypt)**

**8:00-09:30pm**

**CDT European Session (2)**

20 min each talk and 10 min discussion

**Moderators**

***Abdel Fatah Ferer***

***Wagdy Ayad***

**Commentators**

***Ahmed El Hawary***

***Ahmed El Ghalid***

***Hazem Khamis***

***Mohamed Zaki***

***Nasser Taha***

***Wael El Naggar***

**Atherosclerosis and cholesterol lowering a historical perspective.**

***Peter Jan Lansberg***

***(Amsterdam, Netherlands)***

**Management of atrial fibrillation in congestive heart failure**

***Finn Gustafsson***

***(Copenhagen , Denmark)***

**Lipid Management 2010, an update on recent trials and controversies**

***Peter Jan Lansberg***

***(Amsterdam, Netherlands)***

**Cardiovascular complications to new anti-cancer drugs**

***Finn Gustafsson***

***(Copenhagen , Denmark)***

**09:30-10:00 pm Closing remarks**

***Aly Ramzy***

***Faiez Zannad***

***Mohamed Sobhy***